Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NovaBiotics has further secured the global intellectual property (IP) position of its drug Novexatin, a topical treatment for fungal nail infection, through recent patent grants in the US, EU and other territories worldwide.
Subscribe to our email newsletter
With this patents grant Novexatin, currently in phase 2b-ready clinical trial stage, moves closer to further clinical development and commercialisation.
NovaBiotics’ granted and pending IP not only protects the use of the core structure of Novexatin, but of a related family of anti-infective peptides derived from the same technology platform.
The company’s current antifungal product portfolio also includes Novamycin, a candidate treatment for potentially life-threatening blood-stream and deep tissue yeast and mould infections (predominantly Candida).
Novamycin is anticipated to reach a phase I clinical study for a global $5.7bn systemic antifungals market by H1 2011.
In addition, NovaBiotics’ antibacterial peptide drug candidate, NP432 and novel mucolytic agent NM001are now at the early proof of efficacy stage for the treatment of respiratory infections including multi-drug resistant forms and those associated with cystic fibrosis.
NovaBiotics’ IP portfolio covers eight patent families which consist of more than 50 patents pending and granted worldwide.